Literature DB >> 14581531

Construction, rescue, and characterization of vectors derived from ovine atadenovirus.

Peter Löser1, Christian Hofmann, Gerald W Both, Wolfgang Uckert, Moritz Hillgenberg.   

Abstract

Gene transfer vectors derived from ovine atadenovirus type 7 (OAdV) can efficiently infect a variety of mammalian cells in vitro and in vivo to deliver and express transgenes. However, early OAdV vectors were designed on human mastadenovirus principles prior to the complete characterization of OAdV genes and transcripts. The distinctive arrangement of the OAdV genome has suggested ways to improve OAdV vector design and utility. We therefore developed a cosmid-based approach that allows efficient construction of recombinant ovine atadenovirus genomes in which the transgene is inserted at one of three sites. Viruses were rescued by transfection of viral DNA into a new ovine fetal skin fibroblast producer cell line, HVO156. The suitability of the three insertion sites was compared with respect to virus rescue efficiency, gene expression levels, and genetic stability of the vectors. We found that one vector with a transgene inserted at site 1, between the pVIII and fiber genes, was unstable. Only one vector that carried a transgene at site 2, near the right end of the genome, together with a nearby deletion was rescued. In contrast, several vectors with different transgenes inserted in site 3, between the E4 and RH transcription units, were repeatedly rescued, and these vectors were stable over at least four passages. Transgene orientation in site 3 had only little effect on expression. Finally, a vector carrying a human factor IX cDNA at site 3, when administered intravenously, produced nearly physiological levels of human factor IX in mice. The availability of an efficient method for vector construction and the identification of a new insertion site for virus rescue and gene expression substantially enhance the utility of the OAdV vector system.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14581531      PMCID: PMC254277          DOI: 10.1128/jvi.77.22.11941-11951.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity.

Authors:  G Schiedner; N Morral; R J Parks; Y Wu; S C Koopmans; C Langston; F L Graham; A L Beaudet; S Kochanek
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

2.  Construction and transfection of ovine adenovirus genomic clones to rescue modified viruses.

Authors:  S Vrati; E S Macavoy; Z Z Xu; C Smole; D B Boyle; G W Both
Journal:  Virology       Date:  1996-06-01       Impact factor: 3.616

3.  Unique genome arrangement of an ovine adenovirus: identification of new proteins and proteinase cleavage sites.

Authors:  S Vrati; D E Brookes; P Strike; A Khatri; D B Boyle; G W Both
Journal:  Virology       Date:  1996-06-01       Impact factor: 3.616

4.  Gene expression by atypical recombinant ovine adenovirus vectors during abortive infection of human and animal cells in vitro.

Authors:  A Khatri; Z Z Xu; G W Both
Journal:  Virology       Date:  1997-12-08       Impact factor: 3.616

5.  Use of the cosmid adenoviral vector cloning system for the in vitro construction of recombinant adenoviral vectors.

Authors:  S Fu; A B Deisseroth
Journal:  Hum Gene Ther       Date:  1997-07-20       Impact factor: 5.695

6.  Construction of ovine adenovirus recombinants by gene insertion or deletion of related terminal region sequences.

Authors:  Z Z Xu; A Hyatt; D B Boyle; G W Both
Journal:  Virology       Date:  1997-03-31       Impact factor: 3.616

7.  Evaluation of HBV promoters for use in hepatic gene therapy.

Authors:  P Löser; V Sandig; I Kirillova; M Strauss
Journal:  Biol Chem Hoppe Seyler       Date:  1996-03

8.  Sequence of ovine adenovirus homologs for 100K hexon assembly, 33K, pVIII, and fiber genes: early region E3 is not in the expected location.

Authors:  S Vrati; D Boyle; R Kocherhans; G W Both
Journal:  Virology       Date:  1995-06-01       Impact factor: 3.616

9.  Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli.

Authors:  C Chartier; E Degryse; M Gantzer; A Dieterle; A Pavirani; M Mehtali
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

10.  Liposome-encapsulated DNA-mediated gene transfer and synthesis of human factor IX in mice.

Authors:  M Baru; J H Axelrod; I Nur
Journal:  Gene       Date:  1995-08-19       Impact factor: 3.688

View more
  9 in total

1.  Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41.

Authors:  Franck Lemiale; Hedi Haddada; Gary J Nabel; Douglas E Brough; C Richter King; Jason G D Gall
Journal:  Vaccine       Date:  2006-11-28       Impact factor: 3.641

2.  Cryoelectron microscopy map of Atadenovirus reveals cross-genus structural differences from human adenovirus.

Authors:  Radosav S Pantelic; Linda J Lockett; Rosalba Rothnagel; Ben Hankamer; Gerald W Both
Journal:  J Virol       Date:  2008-05-28       Impact factor: 5.103

3.  Induction of both cellular and humoral immunity following a rational prime-boost immunization regimen that incorporates recombinant ovine atadenovirus and fowlpox virus.

Authors:  Cara K Fraser; Kerrilyn R Diener; Erin L Lousberg; Gerald W Both; Larry Ward; Michael P Brown; John D Hayball
Journal:  Clin Vaccine Immunol       Date:  2010-09-01

Review 4.  Production of adenovirus vectors and their use as a delivery system for influenza vaccines.

Authors:  Sai V Vemula; Suresh K Mittal
Journal:  Expert Opin Biol Ther       Date:  2010-10       Impact factor: 4.388

Review 5.  HIV vaccines: progress to date.

Authors:  C Mee Ling Munier; Christopher R Andersen; Anthony D Kelleher
Journal:  Drugs       Date:  2011-03-05       Impact factor: 9.546

6.  Molecular characterization of a bovine adenovirus type 7 (Bovine Atadenovirus F) strain isolated from a systemically infected calf in Germany.

Authors:  Sonja T Jesse; Malgorzata Ciurkiewicz; Ute Siesenop; Ingo Spitzbarth; A D M E Osterhaus; Wolfgang Baumgärtner; Martin Ludlow
Journal:  Virol J       Date:  2022-05-24       Impact factor: 5.913

Review 7.  Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.

Authors:  Estrella Lopez-Gordo; Iva I Podgorski; Nicholas Downes; Ramon Alemany
Journal:  Hum Gene Ther       Date:  2014-03-25       Impact factor: 5.695

Review 8.  Development of nonhuman adenoviruses as vaccine vectors.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Vaccine       Date:  2005-09-23       Impact factor: 3.641

Review 9.  Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based Constructs.

Authors:  Julio Alonso-Padilla; Tibor Papp; Győző L Kaján; Mária Benkő; Menzo Havenga; Angelique Lemckert; Balázs Harrach; Andrew H Baker
Journal:  Mol Ther       Date:  2015-10-19       Impact factor: 11.454

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.